<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D6BC9855-0646-4683-A2E6-565E7CC887DD"><gtr:id>D6BC9855-0646-4683-A2E6-565E7CC887DD</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Kearney</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/20A5B6A1-21F3-4003-813D-939AB0CF88A1"><gtr:id>20A5B6A1-21F3-4003-813D-939AB0CF88A1</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Bentley</gtr:otherNames><gtr:surname>Wheatcroft</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/434630DA-F0E3-406B-B4DA-87FBDEF552FD"><gtr:id>434630DA-F0E3-406B-B4DA-87FBDEF552FD</gtr:id><gtr:firstName>Keith</gtr:firstName><gtr:surname>Channon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/336A04F9-9AC3-4FDF-BFFA-648AC4732AA8"><gtr:id>336A04F9-9AC3-4FDF-BFFA-648AC4732AA8</gtr:id><gtr:firstName>Ajay</gtr:firstName><gtr:surname>Shah</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0901203"><gtr:id>2B3A109D-236C-425A-8698-BF2946F91A3D</gtr:id><gtr:title>Targeting NADPH oxidase to enhance nitric oxide bioavailability in insulin resistance</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901203</gtr:grantReference><gtr:abstractText>The number of people with type 2 diabetes (T2DM) and obesity (the major risk factor for the development of T2DM) has reached epidemic proportions worldwide. 80% of people with T2DM will die from the complications of cardiovascular atherosclerosis (furring of the arteries) resulting in an increased risk of death equivalent to 15 years of aging. We recently demonstrated that despite the use of contemporary secondary prevention therapies patients with T2DM, sustaining an acute myocardial infarction (AMI) or ?heart attack? have not benefited from the improvement in mortality seen in similar patients without T2DM. A central feature of T2DM is resistance to the actions of insulin the hormone that is released to reduce blood sugar this process is known as insulin resistance. Insulin resistance has been demonstrated in many tissues of patients with T2DM. In addition to lowering glucose, insulin is thought to stimulate the release of a substance from the blood vessel wall known as nitric oxide (NO). NO protects the artery against atherosclerosis. It has recently emerged that patients with T2DM have reduced NO. This may therefore contribute to the accelerated atherosclerosis seen in patients with T2DM. We have performed studies that demonstrate a novel mechanism by which insulin resistance may reduce NO actions. We have shown that an enzyme in the blood vessel wall (NADPH oxidase) that produces a damaging gas that mops up NO becomes overactive in insulin resistance. We plan to perform studies examining the effect of reducing the activity of NADPH oxidase in different models of insulin resistance. The results of this study may guide us towards new treatments to prevent AMI in patients with T2DM.</gtr:abstractText><gtr:technicalSummary>Insulin resistance associated with type 2 diabetes, obesity and atherosclerosis is a global health problem. Insulin resistance is characterised by a deleterious proatherosclerotic change in endothelial cell phenotype which is commonly termed endothelial dysfunction. Endothelial dysfunction is characterised by an increase in the production of reactive oxygen species (ROS) which leads to a portfolio of unfavourable effects on the vascular wall principal amongst which is a reduction in the bioavailability of the anti-atherosclerotic signalling molecule nitric oxide (NO). Whilst an association between type 2 diabetes/obesity and reduced NO bioavailability is well established, the mechanisms underlying this relationship remain unclear and as a result therapeutic targets limited. We recently demonstrated using 2 complementary models of insulin resistance that a pathophysiological increase in NADPH oxidase derived ROS may be a key mechanism in insulin resistance induced endothelial dysfunction. In this proposal we plan build on this work and use genetic and pharmacological manipulation of NADPH Oxidase activity in 2 complementary murine models of insulin resistance to definitively establish whether excessive NADPH oxidase and in particular NOX2 NADPH oxidase derived superoxide is a unifying mechanism linking insulin resistance to a proatherosclerotic change in endothelial cell phenotype.</gtr:technicalSummary><gtr:fund><gtr:end>2013-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>493849</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Heart Foundation Personal Chairs</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>F2095777-19E6-4CD5-8E46-63EAEB6A2CA4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF clinical PhD Fellowship</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>FS/12/51/29584</gtr:fundingRef><gtr:id>5B126BE3-8BA6-4EF4-8EEC-3E15C4CC8F2A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>169000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Fellowship</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>FS/14/10/30472</gtr:fundingRef><gtr:id>04BB56E3-4D7D-4C08-BCBA-61A5A937745C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>287000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Project grants</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>BHF Project Grant no. PG/14/54/30939</gtr:fundingRef><gtr:id>7AB81349-CC94-446B-A4AB-70A0BA03A903</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>C0BF1229-432C-4DBA-A0F1-7861AE25A8EC</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1489EB98-4082-42F4-9718-FFB3CCD1094D"><gtr:id>1489EB98-4082-42F4-9718-FFB3CCD1094D</gtr:id><gtr:title>Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/12645ca1dfdac96ee6bac9f4e6513de1"><gtr:id>12645ca1dfdac96ee6bac9f4e6513de1</gtr:id><gtr:otherNames>Sukumar P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5F940756-1BE0-4C97-8804-9EF7A322E07A"><gtr:id>5F940756-1BE0-4C97-8804-9EF7A322E07A</gtr:id><gtr:title>Orai3 Surface Accumulation and Calcium Entry Evoked by Vascular Endothelial Growth Factor.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad7968d586527c1fd3f76aeabf35ac38"><gtr:id>ad7968d586527c1fd3f76aeabf35ac38</gtr:id><gtr:otherNames>Li J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2BFF19A1-168D-4B89-BD97-FDB27CE64DE8"><gtr:id>2BFF19A1-168D-4B89-BD97-FDB27CE64DE8</gtr:id><gtr:title>Insulin resistance impairs circulating angiogenic progenitor cell function and delays endothelial regeneration.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0939490726524a6c5774dcc066f153f2"><gtr:id>0939490726524a6c5774dcc066f153f2</gtr:id><gtr:otherNames>Kahn MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0FCF0C3C-02D4-4FDB-9D6E-7DE29E4C7ABC"><gtr:id>0FCF0C3C-02D4-4FDB-9D6E-7DE29E4C7ABC</gtr:id><gtr:title>Endothelium-specific insulin resistance leads to accelerated atherosclerosis in areas with disturbed flow patterns: a role for reactive oxygen species.</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aee798430ac80ab034fed8a9d79504c9"><gtr:id>aee798430ac80ab034fed8a9d79504c9</gtr:id><gtr:otherNames>Gage MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9150</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7DD6C03A-A5C5-4F07-AF9B-E946D837C314"><gtr:id>7DD6C03A-A5C5-4F07-AF9B-E946D837C314</gtr:id><gtr:title>Constitutively active TRPC channels of adipocytes confer a mechanism for sensing dietary fatty acids and regulating adiponectin.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/12645ca1dfdac96ee6bac9f4e6513de1"><gtr:id>12645ca1dfdac96ee6bac9f4e6513de1</gtr:id><gtr:otherNames>Sukumar P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E12DB4FD-FA35-49B9-A0DB-8C666FEAEBF2"><gtr:id>E12DB4FD-FA35-49B9-A0DB-8C666FEAEBF2</gtr:id><gtr:title>Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e7baed564e46d5f5ab8c1a0ff88a058"><gtr:id>3e7baed564e46d5f5ab8c1a0ff88a058</gtr:id><gtr:otherNames>Magwenzi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901203</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>